FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value

被引：36

作者：

Markova, J. ^{[1
]}

Kobe, C. ^{[2
]}

Skopalova, M.

Klaskova, K. ^{[1
]}

Dedeckova, K. ^{[3
]}

Plutschow, A. ^{[4
]}

Eich, H. T.

Dietlein, M. ^{[2
]}

Engert, A. ^{[5
,6
]}

Kozak, T. ^{[1
]}

机构：

[1] Charles Univ Prague, Fac Med 3, Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague, Czech Republic

[2] Univ Cologne, Dept Nucl Med, Cologne, Germany

[3] Charles Univ Prague, Univ Hosp Na Bulovce, Fac Med 1, Inst Radiat Oncol, Prague, Czech Republic

[4] Univ Cologne, Dept Radiat Oncol, Cologne, Germany

[5] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[6] Univ Cologne, German Hodgkin Study Grp, Cologne, Germany

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷 / 07期

关键词：

BEACOPP; chemotherapy; Hodgkin's lymphoma; PET; response assessment; POSITRON-EMISSION-TOMOGRAPHY; PROGRESSION-FREE; EARLY INTERIM; FREE SURVIVAL; DISEASE; STANDARD; REGIMEN;

D O I：

10.1093/annonc/mdn768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients and methods: From January 2004 to March 2007, 50 patients with newly diagnosed HL in clinical stages IIB with large mediastinal mass or extranodal disease, III and IV were treated according to the HD15 protocol of the German Hodgkin Study Group. All patients received a PET scan after four cycles of BEACOPP (PET-4). Results: Of the overall group, 14 of 50 patients had a positive PET-4 while 36 had a negative PET-4. At a median observation time of 25 months, 2 of the 14 patients with a positive PET-4 had progressed or relapsed, while there was no progression or relapse in PET-4-negative patients. Conclusion: Our results indicate a very good negative predictive value of PET-4 in advanced-stage HL patients treated with BEACOPP.

引用

页码：1270 / 1274

页数：5

共 50 条

[1] EARLY AND LATE RESPONSE ASSESSMENT WITH FDG-PET AFTER BEACOPP-BASED CHEMOTHERAPY IN ADVANCED-STAGE HODGKIN LYMPHOMA PATIENTS HAS A HIGH NEGATIVE PREDICTIVE VALUE
Markova, J.
Kobe, C.
Skopalova, M.
Zikavska, L.
Vernerova, Z.
Klaskova, K.
Dedeckova, K.
Eich, H. T.
Dietlein, M.
Fuchs, M.
Engert, A.
Kozak, T.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 33 - 33
[2] Assessment of Early Treatment Response after 4 Cycles of Chemotherapy using FDG-PET in Patients with Advanced-Stage Hodgkin Lymphoma
Kobe, C.
Markova, J.
Skopalova, M.
Klaskova, K.
Dedeckova, K.
Pluetschow, A.
Eich, H. T.
Dietlein, M.
Engert, A.
Kozak, T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S252 - S253
[3] eAssessment of Early Treatment Response after 4 Cycles of Chemotherapy using FDG-PET in Patients with Advanced-Stage Hodgkin Lymphoma
Kobe, C.
Markova, J.
Skopalova, M.
Klaskova, K.
Dedeckova, K.
Pluetschow, A.
Eich, H. T.
Dietlein, M.
Engert, A.
Kozak, T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (SUPPL 2) : 252 - 253
[4] RESPONSE ASSESSMENT AFTER 4 CYCLES OF BEACOPP USING FDG-PET IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA
Markova, J.
Kobe, C.
Skopalova, M.
Dedeckova, K.
Mocikova, H.
Klaskova, K.
Kahraman, D.
Dietlein, M.
Kozak, T.
ANNALS OF ONCOLOGY, 2011, 22 : 160 - 160
[5] Response assessment after 4 cycles of beacopp using FDG-PET in patients with advanced-stage hodgkin lymphoma
Markova, J.
Kahraman, T. D.
Kobe, C.
Skopalova, M.
Dedeckova, K.
Gaherova, L.
Dietlein, M.
Kozak, T.
ONKOLOGIE, 2011, 34 : 132 - 132
[6] FDG-PET for assessment of early therapy response after 4 cycles of chemotherapy in advanced stage Hodgkin lymphoma
Markova, J.
Skopalova, M.
Kobe, C.
Klaskova, K.
Zikavska, L.
Polivka, J.
Vernerova, Z.
Kamaradova, K.
Dedeckova, K.
Kozak, T.
ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
[7] Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma
Adams, Hugo J. A.
Kwee, Thomas C.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 129 - 131
[8] Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma
Adams, Hugo J. A.
Kwee, Thomas C.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (06) : 491 - 498
[9] EARLY DETERMINATION OF TREATMENT SENSITIVITY IN HODGKIN LYMPHOMA: FDG-PET/CT AFTER ONE CYCLE OF THERAPY HAS A HIGHER NEGATIVE PREDICTIVE VALUE THAN AFTER TWO CYCLES OF CHEMOTHERAPY
Hutchings, M.
Kostakoglu, L.
Zaucha, J. M.
Malkowski, B.
Biggi, A.
Danielewicz, I.
Loft, A.
Specht, L.
Coleman, M.
ANNALS OF ONCOLOGY, 2011, 22 : 138 - 139
[10] Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee
Dann, Eldad J.
Paltiel, Ora
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 131 - 133

← 1 2 3 4 5 →